A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Eligibility
Sex
MALE
Min age
18 Years
Max age
115 Years
Healthy volunteers
No
Inclusion criteria:
* Evidence of 177Lu-PSMA-617 use on or after 01 January 2021.
* Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617.
* Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617.
* Diagnosis of mCRPC prior to or on the index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
* Age ≥18 years at index.
Exclusion criteria:
• None.
Primary outcome measure(s)
Number of Patients by Number of Lines of Therapy (LOTs) Between mCRPC Diagnosis and Index Date — Baseline The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
Number of Patients by Number and Type of Prior Therapies Indicated for Advanced Prostate Cancer (PC) — Baseline Number of patients by number and type of prior ARPI, taxane, 177Lu-PSMA-617, and other therapies indicated for advanced PC.
Number of Patients by Number of Prostate-specific Membrane Antigen (PSMA) Scans — Baseline up to approximately 5 years
Number of Patients by Timing of PSMA Scans — Baseline up to approximately 5 years Timing of scans is categorized as pre-mCRPC diagnosis, post-mCRPC diagnosis but pre-index date, and post-index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
Number of Patients by Number of Post-index LOTs — Up to approximately 5 years
Number of Patients by Type of Therapy at Each Post-index LOT — Up to approximately 5 years
Time From Index Date to Next Therapy Initiation — Up to approximately 5 years The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.